ArticleFrontiers in pharmacology2025

YX-112, a novel celastrol-derived PROTAC, inhibits the development of triple-negative breast cancer by targeting the degradation of multiple proteins.

Yongxue Gu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.